scholarly journals Recombinant luteinizing hormone supplementation in assisted reproductive technology: a review of literature

2021 ◽  
Vol 26 (1) ◽  
Author(s):  
Maryam Eftekhar ◽  
Nasim Tabibnejad
Keyword(s):  
Luteinizing Hormone ◽  
Assisted Reproductive Technology ◽  
Ovarian Stimulation ◽  
Ovarian Function ◽  
Hypogonadotropic Hypogonadism ◽  
Poor Responder ◽  
Reproductive Technology ◽  
Main Role ◽  
Main Body ◽  
Art Outcome

Abstract Background Luteinizing hormone (LH) has the main role in ovarian function in both natural and artificial cycles. A normal LH concentration during controlled ovarian hyperstimulation is positively correlated to the number and quality of retrieved oocytes and resulting embryos. Main body of the abstract In this study, we reviewed whether rLH administration, adjunct to the ovarian stimulation regimen, could improve clinical outcomes. The literature review showed that rLH supplementation improves assisted reproductive technology (ART) outcomes among women with hypogonadotropic hypogonadism, and hyporesponsive women to follicle-stimulating hormone monotherapy. Besides, rLH supplementation has advantages for poor responder women 36–39 years of age. Even though the data suggested no priority regarding the LH source for improving ART outcome, women with different LH polymorphisms who did not respond similarly to ovarian stimulation may benefit from adjuvant rLH therapy. Conclusion rLH usage for improving ART outcome should be scrutinized via well-designed studies considering the subgroups of infertile women who benefit the most from rLH adjuvant therapy, the type of ovarian stimulation protocol to which rLH would be added, and also the exact dosage, as well as the proper timing (during or prior to a cycle).

scholarly journals Analysis of the clinical efficiency of human menopausal gonadotropins in the assisted reproductive technology program

2021 ◽  
pp. 34-41
Author(s):  
Yu. A. Drapkina ◽  
N. P. Makarova ◽  
V. Yu. Smolnikova
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Stimulation ◽  
Ovarian Function ◽  
Laboratory Data ◽  
Reproductive Technology ◽  
Gonadotropin Releasing Hormone ◽  
Human Menopausal Gonadotropin ◽  
Technology Program ◽  
Releasing Hormone ◽  
Technology Programs

Introduction. Comparative analysis of urinary and recombinant gonadotropins is ongoing to improve the efficiency of assisted reproductive technology programs. Particular interest focused on the identification of individual groups of patients with maximal efficacy of using certain ovarian stimulation drugs in an assisted reproductive technology program.Objective. To review the application of Menopur Multidose 1200 IU for ovarian stimulation in assisted reproductive technology protocols with gonadotropin-releasing hormone agonists (GnRH) or gonadotropin-releasing hormone antagonists (GnRH antagonists) in the current clinical practice.Materials and methods. The study retrospectively enrolled 4,080 women aged 20-43 years. Ovarian stimulation in the Assisted Reproductive Technology program was performed using the GnRH antagonist protocol in 65.8% of patients and the GnRH agonist protocol with Menopur Multidose 1200 IU with or without the additional Menopur 75 IU in 34.2% of women.Results. Clinical and laboratory data of the patients, stimulated cycle parameters, characteristics of the embryological stage, and results of the assisted reproductive technology program were analyzed. The frequency of obtaining degenerated oocytes did not exceed 5%. The relative number of blastocysts of good quality was 59.9%, while for patients in the older age group, the figure was 54.6. The average pregnancy rate in patients in the “Menopur Multidose 1200 IU p/k” group was 39.3%, which corresponds to high-performance indicators of the assisted reproductive technology program.Conclusions. Administration of highly purified human menopausal gonadotropin (hMG) (Menopur Multidose 1200 IU) to stimulate ovarian function in patients of different ages is accompanied by an adequate number of mature oocytes, good quality blastocysts, and satisfactory clinical pregnancy rates. Thus, highly purified human menopausal gonadotropin is not inferior to recombinant follicle-stimulating hormone(r-FSH) concerning the efficacy of assisted reproductive technology programs.

scholarly journals Endometrial morphology and modulation of hormone receptors during ovarian stimulation for assisted reproductive technology cycles

2011 ◽  
Vol 95 (3) ◽  
pp. 1037-1041 ◽  
Author(s):  
Laura Detti ◽  
Ghassan M. Saed ◽  
Nicole M. Fletcher ◽  
Michael L. Kruger ◽  
Michelle Brossoit ◽  
...  
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Stimulation ◽  
Hormone Receptors ◽  
Reproductive Technology ◽  
Technology Cycles

Influence of gonadotropins on ovarian follicle growth and developmentin vivoandin vitro

Zygote ◽  
2017 ◽  
Vol 25 (3) ◽  
pp. 235-243 ◽  
Author(s):  
Maxim Filatov ◽  
Yulia Khramova ◽  
Elena Parshina ◽  
Tatiana Bagaeva ◽  
Maria Semenova
Keyword(s):  
Luteinizing Hormone ◽  
Assisted Reproductive Technology ◽  
Ovarian Follicle ◽  
Follicle Stimulating Hormone ◽  
Reproductive Technology ◽  
Present Review ◽  
Follicle Growth ◽  
Therapeutic Practice ◽  
Gonadotropic Hormones

SummaryGonadotropins are the key regulators of ovarian follicles development. They are applied in therapeutic practice in assisted reproductive technology clinics. In the present review we discuss the basic gonadotropic hormones – recombinant human follicle-stimulating hormone, its derivatives, luteinizing hormone and gonadotropin serum of pregnant mares, their origin, and application in ovarian follicle systems inin vitroculture systems.

scholarly journals Outcomes and Recommendations of an Indian Expert Panel for Improved Practice in Controlled Ovarian Stimulation for Assisted Reproductive Technology

2017 ◽  
Vol 2017 ◽  
pp. 1-14 ◽  
Author(s):  
Baiju Ahemmed ◽  
Vani Sundarapandian ◽  
Rohit Gutgutia ◽  
Sathya Balasubramanyam ◽  
Richa Jagtap ◽  
...  
Keyword(s):  
Assisted Reproductive Technology ◽  
Ovarian Stimulation ◽  
Strong Association ◽  
Reproductive Technology ◽  
Data Availability ◽  
Controlled Ovarian Stimulation ◽  
Cohort Size ◽  
Serum Progesterone ◽  
Vitro Fertilization

Purpose.To improve success of in vitro fertilization (IVF), assisted reproductive technology (ART) experts addressed four questions. What is optimum oocytes number leading to highest live birth rate (LBR)? Are cohort size and embryo quality correlated? Does gonadotropin type affect oocyte yield? Should “freeze-all” policy be adopted in cycles with progesterone >1.5 ng/mL on day of human chorionic gonadotropin (hCG) administration?Methods.Electronic database search included ten studies on which panel gave opinions for improving current practice in controlled ovarian stimulation for ART.Results.Strong association existed between retrieved oocytes number (RON) and LBRs. RON impacted likelihood of ovarian hyperstimulation syndrome (OHSS). Embryo euploidy decreased with age, not with cohort size. Progesterone > 1.5 ng/dL did not impair cycle outcomes in patients with high cohorts and showed disparate results on day of hCG administration.Conclusions.Ovarian stimulation should be designed to retrieve 10–15 oocytes/treatment. Accurate dosage, gonadotropin type, should be selected as per prediction markers of ovarian response. Gonadotropin-releasing hormone (GnRH) antagonist based protocols are advised to avoid OHSS. Cumulative pregnancy rate was most relevant pregnancy endpoint in ART. Cycles with serum progesterone ≥1.5 ng/dL on day of hCG administration should not adopt “freeze-all” policy. Further research is needed due to lack of data availability on progesterone threshold or index.

Sign in / Sign up

Export Citation Format

Share Document